TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8872129

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg IK-HIR02 (IV)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg IK-HIR02 (IV)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg IK-HIR02 (IV)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg IK-HIR02 (SC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg IK-HIR02 (SC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg IK-HIR02 (SC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg IK-HIR02 (SC, b.i.d.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hirudin (0.7 micrograms/ml) as anticoagulant
Number of subjects: 18
Study: 1900575

Group type: EXPERIMENTAL
Intervention: Thyroxine (100 micrograms) and Methimazole (10 mg)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo and Methimazole (10 mg)
Number of subjects: 109
Study: 6823860

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (diuretic)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Clonidine (centrally acting agent)
Number of subjects: 29
Study: 29746446

Group type: EXPERIMENTAL
Intervention: Corner Pocket technique (20 mL local anesthetic injected primarily in the corner pocket)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Neural Cluster technique (20 mL local anesthetic injected primarily inside the neural cluster)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Corner Pocket technique
Number of subjects: 36

Group type: COMPARATOR
Intervention: Neural Cluster technique
Number of subjects: 36
Study: 28514618

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 160

Group type: COMPARATOR
Intervention: All exercise groups
Number of subjects: 160
Study: 26143238

Group type: EXPERIMENTAL
Intervention: Core decompression with concentrated bone marrow injection (Group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Core decompression without bone marrow injection (Group B)
Number of subjects: 28
Study: 23978002

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITNs)
Number of subjects: 0
Study: 20452184

Group type: EXPERIMENTAL
Intervention: Probiotic capsules containing Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium lactis, and Streptococcus thermophiles for 6 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Probiotic capsules for patients with baseline ammonia levels > 50 mmol/L
Number of subjects: 36
Study: 17600650

Group type: EXPERIMENTAL
Intervention: Web-based feedback (WI)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Web-based feedback plus motivational interviewing (MI)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study: 17000789

Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dopamine (2 mcg x kg(‐1) x min(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 60
Study: 14511455

Group type: EXPERIMENTAL
Intervention: Imagery enhanced learning (I-learning) using low-cost Virtual Reality technology for motor imagery.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Virtual training
Number of subjects: 0
Study: 10782604

Group type: EXPERIMENTAL
Intervention: Pulse oximetry available to paramedics
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pulse oximetry available to paramedics
Number of subjects: 0
Study: 8993489

Group type: EXPERIMENTAL
Intervention: Tacrine (80, 120, or 160 mg/day)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Tacrine
Number of subjects: 460
Study: 1614100

Group type: EXPERIMENTAL
Intervention: Topical diclofenac (Voltaren Ophtha)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 6369584

Group type: EXPERIMENTAL
Intervention: Grassi test
Number of subjects: 48

Group type: COMPARATOR
Intervention: No test (non-Grassi)
Number of subjects: 48
Study: 29541824

Group type: EXPERIMENTAL
Intervention: Jaundiced group
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 27423583

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Soy protein (Control)
Number of subjects: 32
Study: 24739766

Group type: EXPERIMENTAL
Intervention: Penn Resiliency Program (PRP)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 23768270

Group type: EXPERIMENTAL
Intervention: Core isometric endurance training (n=5)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Core isotonic strength training (n=5)
Number of subjects: 10
Study: 22432561

Group type: EXPERIMENTAL
Intervention: CoQ(10) (NPN 02176955)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CoQ(10)‐P5P‐PC
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CoQ(10) (DIN 02231736)
Number of subjects: 21
Study: 18189160

Group type: EXPERIMENTAL
Intervention: FEC(75)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: FEC(90)
Number of subjects: 147
Study: 16670544

Group type: EXPERIMENTAL
Intervention: Surgically treated clubfoot
Number of subjects: 7
Study: 11940136

Group type: EXPERIMENTAL
Intervention: BOMP index
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: EIB index
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Experimental gingivitis (EG)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Floss (FL)
Number of subjects: 43
Study: 10235108

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 1775

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1775
Study: 7565975

Group type: EXPERIMENTAL
Intervention: Nurse-directed, multidisciplinary intervention
Number of subjects: 282

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 282
Study: 2251873

Group type: EXPERIMENTAL
Intervention: B subunit‐killed whole cell (BS‐WC)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Killed whole cell (WC)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Escherichia coli K12 strain (K12)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: BS-WC, WC, K12
Number of subjects: 53
Study: 6103706

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Lorazepam 2.5 mg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210

Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Flunitrazepam 2 mg
Number of subjects: 210
Study: 31583738

Group type: EXPERIMENTAL
Intervention: Bioimpedance Spectroscopy (BIS)
Number of subjects: 135
Study: 31123915

Group type: EXPERIMENTAL
Intervention: EF-training condition (working memory, inhibition, cognitive flexibility training)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 61
Study: 27793396

Group type: EXPERIMENTAL
Intervention: Alirocumab 75/150 mg every 2 weeks (Q2W)
Number of subjects: 4915

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W
Number of subjects: 4915

Group type: COMPARATOR
Intervention: Control (placebo or ezetimibe)
Number of subjects: 4915
Study: 25866250

Group type: EXPERIMENTAL
Intervention: Sevelamer Carbonate (SC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate (LC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sevelamer Hydrochloride (SH)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Proton Pump Inhibitor (PPI) therapy
Number of subjects: 24
Study: 24463421

Group type: EXPERIMENTAL
Intervention: E‐Health4Uth home safety intervention
Number of subjects: 1292
Study: 22644174

Group type: EXPERIMENTAL
Intervention: Frovatriptan (F) 2.5 mg
Number of subjects: 346

Group type: COMPARATOR
Intervention: Comparators (Rizatriptan (R) 10 mg, Zolmitriptan (Z) 2.5 mg, Almotriptan (A) 12.5 mg)
Number of subjects: 346
Study: 19765270

Group type: EXPERIMENTAL
Intervention: Switch program (experimental group)
Number of subjects: 1323

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1323
Study: 17202903

Group type: EXPERIMENTAL
Intervention: Fitness training at health clubs (n = 833)
Number of subjects: 6021

Group type: EXPERIMENTAL
Intervention: Multidisciplinary outpatient rehabilitation (n = 468)
Number of subjects: 6021

Group type: EXPERIMENTAL
Intervention: Multidisciplinary inpatient rehabilitation (n = 135)
Number of subjects: 6021

Group type: COMPARATOR
Intervention: Usual insured individual care
Number of subjects: 6021
Study: 15220940

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (single high dose every 4 months)
Number of subjects: 1405
Study: 11144995

Group type: EXPERIMENTAL
Intervention: ARA (adenosine receptor agonist)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hypothetical antagonist
Number of subjects: 13
Study: 10072743

Group type: EXPERIMENTAL
Intervention: Cessation (smoking cessation intervention)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (non-intervention group)
Number of subjects: 3
Study: 7602348

Group type: EXPERIMENTAL
Intervention: Intense therapy (cyclophosphamide 1,000 mg/m2 and cisplatin 100 mg/m2 intravenously every 3 weeks for four courses)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Standard therapy (cyclophosphamide 500 mg/m2 and cisplatin 50 mg/m2 intravenously every 3 weeks for eight courses)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Intense therapy
Number of subjects: 485

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 485
Study: 2186769

Group type: EXPERIMENTAL
Intervention: Warfarin (1 mg daily minidose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 705564

Group type: EXPERIMENTAL
Intervention: CVPP (cyclophosphamide, vinblastine, procarbazine, prednisone)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: CCVPP (CVPP + CCNU)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: CCVPP
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: CVPP
Number of subjects: 191

Group type: COMPARATOR
Intervention: CCVPP vs CVPP
Number of subjects: 191
Study: 30899994

Group type: EXPERIMENTAL
Intervention: Abaloparatide
Number of subjects: 2463

Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 2463
Study: 28780236

Group type: EXPERIMENTAL
Intervention: Tenecteplase 0.4 mg/kg (max 40 mg)
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Alteplase 0.9 mg/kg (max 90 mg)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 1100
Study: 26606120

Group type: EXPERIMENTAL
Intervention: Vaginal mesh
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sacrospinous ligament fixation
Number of subjects: 70
Study: 23098630

Group type: EXPERIMENTAL
Intervention: Crystalens HD silicone accommodating IOL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetraflex acrylic accommodating IOL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tecnis 1‐piece monofocal (nonaccommodating) control IOL
Number of subjects: 0
Study: 22276413

Group type: EXPERIMENTAL
Intervention: Exercise prior to exposure (30 min on a cycle ergometer, including 20 min at moderate intensity)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Exercise after exposure (30 min on a cycle ergometer, including 20 min at moderate intensity)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No-exercise (control group)
Number of subjects: 48
Study: 19841760

Group type: EXPERIMENTAL
Intervention: Tri‐S Bond (Kuraray)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G‐Bond (GC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (water storage for 24 h)
Number of subjects: 0
Study: 17376791

Group type: EXPERIMENTAL
Intervention: Tenofovir 300 mg once daily
Number of subjects: 0
Study: 14983571

Group type: EXPERIMENTAL
Intervention: Problem-based learning (n = 10)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Traditional lecture (n = 12)
Number of subjects: 22
Study: 10378549

Group type: EXPERIMENTAL
Intervention: Diagnostic bronchoscopy
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Empiric anti-PCP therapy
Number of subjects: 1500
Study: 8876274

Group type: EXPERIMENTAL
Intervention: Suprapubic catheterisation (SPC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transurethral catheterisation (TUC)
Number of subjects: 50
Study: 1498073

Group type: EXPERIMENTAL
Intervention: CVPP plus RT (3000 cGy)
Number of subjects: 151

Group type: COMPARATOR
Intervention: CVPP alone
Number of subjects: 151
Study: 6823470

Group type: EXPERIMENTAL
Intervention: Isometric exercise with electromyographic biofeedback
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isometric exercise without electromyographic biofeedback
Number of subjects: 30

Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 30
Study: 3959798

Group type: EXPERIMENTAL
Intervention: Preoperative gamma-therapy at a dose of 19.5 Gy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preoperative gamma-therapy at a dose of 30 Gy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preoperative gamma-therapy at a dose of 40 Gy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 40
Study: 31734084

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus an oral antidepressant
Number of subjects: 0

Group type: COMPARATOR
Intervention: New oral antidepressant
Number of subjects: 0
Study: 28991048

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 300 mg group (100 mg initial bolus followed by continuous infusion of 300 mg daily for 5 days)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Hydrocortisone 200 mg group (50 mg intravenous bolus every 6 h during 7 days)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Nonresponders (CST response of 9 μg/dL or less)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Baseline blood cortisol
Number of subjects: 99
Study: 27787476

Group type: EXPERIMENTAL
Intervention: Whole-body vibration at 12 Hz
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Whole-body vibration at 26 Hz
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Knee flexion at 40°
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Increased vibration frequency
Number of subjects: 13
Study: 25223164

Group type: EXPERIMENTAL
Intervention: Chewing gauze soaked with 20 ml of 2% lidocaine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Chewing gauze soaked with saline
Number of subjects: 24
Study: 22812440

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (no chewing gum)
Number of subjects: 57
Study: 20685723

Group type: EXPERIMENTAL
Intervention: Enhanced secondary prevention (additional advice, motivational interviewing and telephone support)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 52
Study: 18213382

Group type: EXPERIMENTAL
Intervention: SAVVY (1.0% C31G)
Number of subjects: 2153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2153

Group type: COMPARATOR
Intervention: SAVVY vs Placebo
Number of subjects: 2153

Group type: EXPERIMENTAL
Intervention: SAVVY
Number of subjects: 2153
Study: 15991068

Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 12672732

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 10023125

Group type: EXPERIMENTAL
Intervention: Recombinant human nerve growth factor (rhNGF) administered at doses of 0.1 or 0.3 microg/kg subcutaneously 3 days a week for 6 months.
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Recombinant human nerve growth factor (rhNGF) administered at doses up to 1.0 microg/kg intravenously or subcutaneously for up to 12 doses in phase I studies.
Number of subjects: 209
Study: 8678284

Group type: EXPERIMENTAL
Intervention: Clonidine (bolus 30 micrograms)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Piritramide (bolus 1.5 mg)
Number of subjects: 40
Study: 1987875

Group type: EXPERIMENTAL
Intervention: Water-tank lithotriptor (group A)
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Water-cushion lithotriptor at low energy levels (group B)
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Water-cushion lithotriptor at high energy levels (group C)
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Bile acid therapy compliance
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 711
Study: 6857584

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg four times daily)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 2
Study: 31646460

Group type: EXPERIMENTAL
Intervention: KIM-1 staining
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: KIM-1/sCr ratio
Number of subjects: 184
Study: 29447379

Group type: EXPERIMENTAL
Intervention: Treadmill exercise 24 hours preoperatively (EX group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard presurgical procedures (Control group)
Number of subjects: 20
Study: 25601896

Group type: EXPERIMENTAL
Intervention: Intramuscular single dose of 300,000 IU vitamin D3
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 60
Study: 25024660

Group type: EXPERIMENTAL
Intervention: AASM recommended EEG montage (F4‐M1, C4‐M1, O2‐M1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: AASM acceptable EEG montage (Fz‐Cz, C4‐M1, Oz‐Cz)
Number of subjects: 50
Study: 23127390

Group type: EXPERIMENTAL
Intervention: CT-based sizing recommendations for TAVR
Number of subjects: 120

Group type: COMPARATOR
Intervention: TEE sizing
Number of subjects: 120
Study: 20544489

Group type: EXPERIMENTAL
Intervention: Aerobic training (12 weeks, 5 days a week)
Number of subjects: 18
Study: 17953631

Group type: EXPERIMENTAL
Intervention: Antioxidant pool (AP) supplementation for 2 months before and 6 months during NB‐UVB treatment
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Antioxidant pool (AP) supplementation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 16367987

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 210

Group type: COMPARATOR
Intervention: Lofexidine
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Not completing detoxification (both groups)
Number of subjects: 210
Study: 12037659

Group type: EXPERIMENTAL
Intervention: 100 ml tomato juice with 300 mg HCA
Number of subjects: 24

Group type: COMPARATOR
Intervention: 100 ml tomato juice (placebo)
Number of subjects: 24
Study: 12555375

Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine associated with enalapril or hydrochlorothiazide)
Number of subjects: 2418

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2418
Study: 8904587

Group type: EXPERIMENTAL
Intervention: 30% O2
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 75% O2 (isocapnic)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 75% O2 (poikilocapnic)
Number of subjects: 8
Study: 1800166

Group type: EXPERIMENTAL
Intervention: Topical 2-(2-Hydroxy-4-methylphenyl) Aminothiazole Hydrochloride 0.1% (CBS 113A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 6391903

Group type: EXPERIMENTAL
Intervention: Olive oil (30 ml)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Linseed oil (30 ml)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 29
Study: 31542293

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 0
Study: 29526850

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment (Transcranial Direct Current Stimulation + Positive psychotherapy)
Number of subjects: 0
Study: 26953280

Group type: EXPERIMENTAL
Intervention: U‐300 insulin glargine
Number of subjects: 6

Group type: COMPARATOR
Intervention: U‐100 insulin glargine
Number of subjects: 6
Study: 25070099

Group type: COMPARATOR
Intervention: 7-day standard triple therapy (pantoprazole, clarithromycin, amoxicillin for 7 days)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (pantoprazole and amoxicillin for 5 days, followed by pantoprazole, clarithromycin, and metronidazole for a further 5 days)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: 7-day concomitant therapy (pantoprazole, clarithromycin, amoxicillin, and metronidazole for 7 days)
Number of subjects: 307
Study: 23231777

Group type: EXPERIMENTAL
Intervention: Beetroot and apple juice (BJ)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo juice (PL)
Number of subjects: 30
Study: 19898821

Group type: EXPERIMENTAL
Intervention: PFC Sigma fixed‐bearing total knee replacement
Number of subjects: 120

Group type: COMPARATOR
Intervention: PFC Sigma rotating‐platform total knee replacement
Number of subjects: 120
Study: 18382824

Group type: EXPERIMENTAL
Intervention: Leg exercise group (n = 32)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Arm exercise group (n = 31)
Number of subjects: 63
Study: 16029670

Group type: EXPERIMENTAL
Intervention: 4% hydroquinone/0.3% retinol cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.05% tretinoin emollient cream
Number of subjects: 0
Study: 12482153

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic living-donor nephrectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open donor nephrectomy
Number of subjects: 100
Study: 10439767

Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion (0.5 microgram.kg‐1.min‐1 i.v.)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 100
Study: 7874593

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography in patients with heart diseases
Number of subjects: 85

Group type: COMPARATOR
Intervention: Doppler echocardiography in healthy volunteers
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography in patients
Number of subjects: 85
Study: 2121150

Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol (30 g in red port and wine) consumed during a standard dinner
Number of subjects: 16